Insmed to Present at the 2026 Goldman Sachs Annual Global Healthcare Conference
Insmed (Nasdaq: INSM) announced that management will present at the 2026 Goldman Sachs Annual Global Healthcare Conference in Miami on Tuesday, June 9, 2026, at 10:00 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Insmed (Nasdaq: INSM) announced that management will present at the 2026 Goldman Sachs Annual Global Healthcare Conference in Miami on Tuesday, June 9, 2026, at 10:00 a.m. ET. A live webcast and 30-day replay will be available on Insmed's investor relations website.
Details
News Market Reaction – INSM
On May 27, the day this news came out, INSM closed 2.27% below the previous close.
Data tracked by StockTitan Argus for the May 27 session.
Key Figures
- Conference date
- June 9, 2026
- Goldman Sachs Annual Global Healthcare Conference presentation date
- Presentation time
- 10:00 a.m. ET
- Scheduled time for Insmed’s conference presentation
- Webcast archive period
- 30 days
- Duration the conference webcast will remain available on Insmed’s site
Historical Context
-
Strong revenue growth and reiterated 2026 guidance but shares fell sharply.
-
Bronchiectasis education initiative with Ty Pennington to boost disease awareness.
-
Multiple ATS 2026 abstracts including late-breaking Phase 3b ENCORE results.
-
Planned presentations at BofA and RBC healthcare conferences with webcasts.
-
Scheduled Q1 2026 results release and business update conference call.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
This event will be webcast live and can be accessed by visiting the investor relations section of the Company's website at www.insmed.com. This webcast will be archived for a period of 30 days following the conclusion of this live event.
About Insmed
Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's most advanced programs are in pulmonary and inflammatory conditions, including two approved therapies to treat chronic, debilitating lung diseases. The Company's early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, RNA end-joining, and synthetic rescue.
Headquartered in
Contact:
Investors:
Bryan Dunn
Vice President, Investor Relations
(646) 812-4030
investor.relations@insmed.com
Media:
Claire Mulhearn
Vice President, Corporate Communications
(862) 842-6819
media@insmed.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/insmed-to-present-at-the-2026-goldman-sachs-annual-global-healthcare-conference-302782306.html
SOURCE Insmed Incorporated
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.